The Effects of Aronia Melanocarpa Extract on Obese Individuals With Impaired Fasting Blood Glucose

NCT ID: NCT06057389

Last Updated: 2023-09-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-07

Study Completion Date

2025-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obesity is closely related to many chronic diseases such as hypertension, coronary heart disease, hyperlipidemia, type 2 diabetes, fatty liver, certain types of tumors, etc, which are associated with adverse health outcomes. Limiting energy intake is one of the most important treatment measures for weight loss. The fruits of Aronia melanocarpa (Aronia berries) have been found to show multiple bioactivities potentially beneficial to human health, including antidiabetic, anti-infective, antineoplastic, antiobesity, antioxidant and gut microbiota-regulating activities. Thus, it is worth investigating whether consumption of aronia melanocarpa extract have additional benefits in improving anthropometric indicators, glucose and lipid metabolism, inflammatory status, adipocyte cytokines, and intestinal microbiota in obese individuals on the basis of an energy-restricted diet.

Obese individuals will be divided into intervention group and control group in this 8-week trial. Both groups will be given an energy-restricted diet, with an additional dose of aronia melanocarpa extract in capsules in intervention group and an additional dose of maltodextrin in capsules in control group.

Fecal and blood samples from participants before and after the intervention will be collected for the analysis of gut microbiota, glucose and lipid metabolism, inflammatory status, and adipocyte cytokines

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention group

Intervention group: an energy-restricted diet + aronia melanocarpa extract

Group Type EXPERIMENTAL

aronia melanocarpa extract

Intervention Type DIETARY_SUPPLEMENT

aronia melanocarpa extract (each capsule contains 150 mg of anthocyanins and 30 mg of flavonoidst;twice a day,one at a time) combined with an energy-restricted diet

Control group

control group: an energy-restricted diet + maltodextrin

Group Type PLACEBO_COMPARATOR

aronia melanocarpa extract

Intervention Type DIETARY_SUPPLEMENT

aronia melanocarpa extract (each capsule contains 150 mg of anthocyanins and 30 mg of flavonoidst;twice a day,one at a time) combined with an energy-restricted diet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

aronia melanocarpa extract

aronia melanocarpa extract (each capsule contains 150 mg of anthocyanins and 30 mg of flavonoidst;twice a day,one at a time) combined with an energy-restricted diet

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18-40 years
* Simple obese individuals with stable body weight in the last three months before enrollment (28.0kg/m2 ≤ BMI \<35.0kg/m2)
* Impaired fasting blood glucose: Within the last three months before enrollment, the venous fasting blood glucose was between 6.1 and 7.0 mmol/L, and the 2-hour postprandial blood glucose was\<7.8 mmol/L and the glycated hemoglobin (HbA1c) was \< 6.5%

Exclusion Criteria

* Diagnosed patients with diabetes or those who use hypoglycemic drugs
* Patients with concomitant hyperthyroidism or hypothyroidism, or those taking thyroxine tablets
* Those who apply glucocorticoids within 12 weeks
* Individuals with suspected renal dysfunction (female: serum creatinine ≥ 84 µ mol/L; male: serum creatinine ≥ 104 µ mol/L) or suspected liver dysfunction (elevated transaminase \>3 times normal or cirrhosis)
* Secondary obesity (such as thalamic diseases, pituitary diseases, Cushing's syndrome, etc.)
* Previous weight loss surgeries
* Pregnant or lactating individuals
* Individuals with confirmed mental illness or eating disorders
* Women with polycystic ovary syndrome
* Individuals who are allergic or intolerant to experimental products
* Lactose intolerant individuals
* Those who have taken probiotics and/or probiotic drugs or supplements within one month before enrollment
* Those who fail to use intervention agents according to the study protocol or have severely incomplete visit records
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Peking Union Medical College Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

I-23PJ329

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

BK329 and Body Fat Reduction
NCT06628791 COMPLETED NA
Hepatic Glycogen and Fat Oxidation
NCT03593343 COMPLETED NA